Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session

BOSTON, MA, March 18, 2020 – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) during the Muscular Dystrophy Association (MDA) Virtual Clinical Trials Session on Tuesday, March 24, 2020.

Erika L. Finanger, MD, Division of Neurology at Oregon Health and Science University and a Principal Investigator for the Phase 2 MoveDMD, Phase 3 PolarisDMD, and open-label extension GalaxyDMD trials, will give an oral presentation titled "Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy Is Associated with Age-Normative Growth and Normal Adrenal Function" during the Clinical Trial Presentations session from 11am to 4pm EDT on Tuesday, March 24, 2020. The webcast will be available to registered conference attendees and presented material will be made available on the company website after the session at www.catabasis.com.

About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule designed to inhibit NF-kB that is being developed as a potential foundational therapy for all patients affected by DMD, regardless of their underlying mutation. In DMD the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. Our ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy and safety of edasalonexent for registration purposes. Edasalonexent is also being dosed in the GalaxyDMD open-label extension trial. In our MoveDMD Phase 2 trial and open-label extension, we observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers of muscle health and inflammation. The FDA has granted orphan drug, fast track, and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results, please visit www.catabasis.com.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

###

Investor and Media Contact
Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com